on ADOCIA (EPA:ADOC)
Adocia Reports 2025 Financial Results and Strategic Developments
Adocia, a biopharmaceutical company, announced its 2025 financial results. The cash position was €17.2 million as of December 31, 2025. Key developments include the completion of BioChaperone® Lispro's Phase 3 trials in China by partner Tonghua Dongbao, achieving positive results. The company continued collaboration for BioChaperone® and filed a patent for the AdoXLong™ platform, showing promising preclinical results. A clinical trial application is planned for the AdoShell® platform in Q3 2026.
In 2025, Adocia faced a net loss of €16.6 million, up from a €9.3 million loss in 2024, attributed to lower revenue. Revenue was €1.5 million compared to €9.3 million in the previous year. Post-period, a loan agreement with Vester Finance was secured, extending the cash runway to Q2 2027. Governance changes included appointing Stéphane Boissel as Chairman and Jacky Vonderscher as a Director.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ADOCIA news